LS301-IT

Phase 2Small molecule

IIntegro Theranostics

LS301-IT is one of 102 small molecule programs targeting Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

101

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

Breast CancerActive, not recruiting

Non-Small Cell Lung Cancer (NSCLC)Active, not recruiting

Lung CancerPhase 1

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Non-Small Cell Lung Cancer (NSCLC)Phase 2

Active, not recruiting

Competition

Competitive Landscape

702 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Lexiscan

Astellas

Preclinical

1 2

Voltaren

Novartis

Preclinical

1 3

Zolymbus

AbbVie

Preclinical

1 4

Blenoxane

Bristol-Myers Squibb

Preclinical

1 5

LS301-IT

IIntegro Theranostics

Phase 2

1 6

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 8

Duragesic-100

CCephalon

Preclinical

2 9

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 10

Spravato

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Active, not recruiting

Non-Small Cell Lung Cancer (NSCLC)

NCT07276789

Clinical

Trials by Indication[1]

Breast Cancer1 trial

LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer

Active, not recruiting·IIntegro Theranostics·Phase 1/2·NCT05900986·100 enrolled

Lung Cancer1 trial

A Single Dose, Open-Label, Dose-escalation Study of the Safety and Imaging Characteristics of LS301-IT for Intraoperative Imaging of Lung Cancer

Active, not recruiting·IIntegro Theranostics·Phase 1·NCT06713564·24 enrolled

Non-small Cell Lung Cancer (NSCLC)1 trial

A Phase 2, Open-Label, Multicenter Study to Investigate the Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Lung Cancer Resection

Active, not recruiting·IIntegro Theranostics·Phase 2·NCT07276789·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for LS301-IT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LS301-IT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LS301-IT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Integro Theranostics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IIntegro Theranostics

LS301-IT

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Breast Cancer1 trial

Lung Cancer1 trial

Non-small Cell Lung Cancer (NSCLC)1 trial

References

Drug Info

Quick Facts

Related News